Top

Published in:

01-05-2010 | Original Research Article

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease

A 2-year prospective, multicentre, cohort study

Authors: Dr Virginie Gardette, Sandrine Andrieu, Maryse Lapeyre-Mestre, Nicola Coley, Christelle Cantet, Pierre-Jean Ousset, Alain Grand, Jean-Louis Monstastruc, Bruno Vellas

Published in: CNS Drugs | Issue 5/2010

Abstract

Background: The efficacy of cholinesterase inhibitors (ChEIs), especially over the long term, is still under discussion. There is a lack of data concerning the optimal drug treatment duration and the reasons for discontinuation, particularly outside the clinical trial setting.

Objective: To identify predictive factors of discontinuation and switch of ChEIs in a real-world setting.

Methods: A multicentre cohort study of 686 patients with mild-to-moderate ambulatory Alzheimer’s disease who were diagnosed in 16 Alzheimer’s disease expert centres in 2000–2 and who were assessed twice yearly for 2 years. The main outcome measure was ChEI discontinuation and switch (analysed using Cox survival analyses).

Results: After 2 years, of the 611 subjects treated with a ChEI at baseline, 100 subjects had switched or discontinued ChEI therapy (incidence rate 12.7 [95% CI 10.2, 15.2] per 100 person-years). The incidences of switching and discontinuation were 9.2 (95% CI 7.0, 11.3) and 3.6 (95% CI 2.3, 4.8) per 100 person-years, respectively. In the multivariate analysis, predictive factors for switching were an ineffective ChEI dose (adjusted hazard ratio [HR_a] = 6.91, 95% CI 3.08, 15.49), rapid cognitive decline (HR_a = 4.10, 95% CI 1.85, 9.05), hospitalization unrelated to Alzheimer’s disease (HR_a = 2.33,95% CI 1.07, 5.09) and anxiety (HR_a= 2.08, 95% CI 1.16, 3.73). Predictive factors of discontinuation were: hospitalization related (HR_a = 9.14, 95% CI 2.69, 31.07) or unrelated (HR_a = 4.23, 95% CI 1.54, 11.59) to Alzheimer’s disease, use of an anticholinergic drug (HR_a = 4.26, 95% CI 1.46, 12.45) and weight loss (HR_a = 3.77, 95% CI 1.15, 12.33).

Conclusions: This study highlights four types of predictors of switch or discontinuation, reflecting disease progression, reconsideration of ChEI benefits, adverse drug reactions to ChEIs and inappropriate concurrent use of anticholinergic drugs. Attention should be paid to anticholinergic agents and prescribers should be given better information about these drugs.

Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008 Mar 4; 148(5): 379–97PubMed

Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57(3): 489–95PubMedCrossRef

Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 2003; 20(10): 777–89PubMedCrossRef

Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57(3): 481–8PubMedCrossRef

Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004 Jun 26; 363(9427): 2105–15PubMedCrossRef

Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008 Mar 4; 148(5): 370–8PubMed

Winblad B, Wimo A, Almkvist O. Outcome measures in Alzheimer’s disease: do they go far enough? Dement Geriatr Cogn Disord 2000 Sep; 11 Suppl. 1: 3–10PubMedCrossRef

Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006 Jul 29; 368(9533): 387–403PubMedCrossRef

Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004 Fall; 11(2): e274–85PubMed

10.

Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007 Oct; 55(10): 1517–23PubMedCrossRef

11.

Kogut SJ, El-Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 2005 Dec; 25(12): 1729–35PubMedCrossRef

12.

Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005 Apr; 11(3): 231–51PubMed

13.

Singh G, Thomas SK, Arcona S, et al. Treatment persistency with rivastigmine and donepezil in a large state Medicaid program. J Am Geriatr Soc 2005 Jul; 53(7): 1269–70PubMedCrossRef

14.

Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer’s disease. Drugs Aging 2005; 22(8): 695–707PubMedCrossRef

15.

Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. The REAL.FR research program on Alzheimer’s disease and its management: methods and preliminary results. J Nutr Health Aging 2003; 7(2): 91–6PubMed

16.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

17.

McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984 Jul; 34(7): 939–44PubMedCrossRef

18.

Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov; 12(3): 189–98PubMedCrossRef

19.

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984 Nov; 141(11): 1356–64PubMed

20.

Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982 Jun; 140: 566–72PubMedCrossRef

21.

Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 Sep 21; 185: 914–9PubMedCrossRef

22.

Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 Dec; 44(12): 2308–14PubMedCrossRef

23.

Guigoz Y, Vellas B, Gary PJ. The Mini Nutritional Assessment: a practical assessment tool for grading the nutritional state of elderly patients. Facts Res Gerontol 1994; Suppl. 2: 113–43

24.

Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980 Dec; 20(6): 649–55PubMedCrossRef

25.

Coley N, Gardette V, Toulza O, et al. Predictive factors of attrition in a cohort of Alzheimer disease patients: the REAL.FR study. Neuroepidemiology 2008; 31(2): 69–79PubMedCrossRef

26.

Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 10th ed. New York: MacGraw Hill, 2001: 175–91

27.

La revue Prescrire, Interactions medicamenteuses, comprendre et decider. Rev Prescrire 2006; 270 Suppl. : 110–4

28.

Soto ME, Andrieu S, Cantet C, et al. Predictive value of rapid decline in Mini Mental State Examination in clinical practice for prognosis in Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 26(2): 109–16PubMedCrossRef

29.

Allison PD. Survival analysis using SAS®: a practical guideline. Cary (NC): SAS Institute Inc., 1995: 158–61

30.

Perras C, Shukla VK, Lessard C, et al. Cholinesterase inhibitors for Alzheimer’s disease: a systematic review of randomized controlled trials (technology report no. 58). Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 2005

31.

Raschetti R, Maggini M, Sorrentino GC, et al. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease. Eur J Clin Pharmacol 2005 Jul; 61(5–6): 361–8PubMedCrossRef

32.

Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 2009 Apr; 18(4): 310–9PubMedCrossRef

33.

Pariente A, Helmer C, Merliere Y, et al. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008 Jul; 17(7): 655–60PubMedCrossRef

34.

National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance no. 111: guidance on the use of donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA111UNGAmended.pdf [Accessed 2010 Feb 26]

35.

Final approved recommendations. Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia; 2006 Mar 9–11; Montreal (QC): 28

36.

Frankfort SV, Appels BA, de Boer A, et al. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry 2005 Dec; 20(12): 1167–71PubMedCrossRef

37.

Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging 2003; 20(6): 437–44PubMedCrossRef

38.

Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007 Feb; 81(2): 235–41PubMedCrossRef

39.

Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8–22; 163(22): 2716–24PubMedCrossRef

40.

Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007; 30(11): 1063–71PubMedCrossRef

41.

Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004 Dec; 52(12): 2082–7PubMedCrossRef

42.

Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50(5): 836–42PubMedCrossRef

43.

Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700000 elderly patients. Drugs Aging 2008; 25(10): 871–7PubMedCrossRef

Title: Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease
A 2-year prospective, multicentre, cohort study
Authors: Dr Virginie Gardette
Sandrine Andrieu
Maryse Lapeyre-Mestre
Nicola Coley
Christelle Cantet
Pierre-Jean Ousset
Alain Grand
Jean-Louis Monstastruc
Bruno Vellas
Publication date: 01-05-2010
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 5/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11318010-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease

A 2-year prospective, multicentre, cohort study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Olanzapine

Medical management of Lennox-Gastaut syndrome

Frontotemporal lobar degeneration

The safety and tolerability of newer antiepileptic drugs in children and adolescents